{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"EP_2388015_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"025-166-514-643-562"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11617,"type":"PATENT","title":"Emory University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":6117,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8292,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: emory AND uni*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5631
Search Applicants and Owners separately: emory AND uni*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5631
a termination sequence encoding for the lambda TO terminator;
a prokaryotic origin of replication;
a selectable marker gene; and
a eukaryotic transcription cassette comprising a vaccine insert encoding one or more immunogens derived from a pathogen."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The vector of Claim 1, wherein the pathogen is a viral pathogen, preferably selected from the group consisting of HIV, measles, influenza, polio and rubella."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The vector of Claim 1, wherein the one or more immunogens is selected from the group consisting of HIV Gag, HIV gp120 HIV Pol, HIV Env, HIV VLP, measles fusion protein, measles hemagglutinin, measles nucleoprotein, influenza hemagglutinin, mutants thereof, and subsequences thereof, preferably selected from the group consisting of HIV Gag, HIV gp120, HIV Pol, HIV Env, and HIV VLP, mutants thereof, and subsequences thereof."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The vector according to Claim 1, wherein the vaccine insert encoding one or more immunogen or immunogens further comprises at least one C3d gene."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["A physiologically acceptable composition, comprising the vector of any of the preceeding claims, for use in a method of immunizing or treating a patient, comprising the step of administering a therapeutically effective amount of the compostion."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["Use of a physiologically acceptable composition comprising the vector of claim 1 for the manufacture of a medicament for immunizing a patient, comprising the step of administering a therapeutically effective amount of the composition."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The use of Claim 6, further comprising the step of subsequently administering a therapeutically effective amount of a composition comprising a recombinant pox virus vector expressing one or more immunogens selected from the group consisting of HIV Gag, HIV gp120, HIV Pol, HIV Env, HIV VLP, measles fusion protein, measles hemagglutinin, measles nucleoprotein, influenza hemagglutinin, mutants thereof, and subsequences thereof, or a composition comprising said recombinant pox virus, preferably wherein the one or more immunogens is selected from the group consisting of HIV Gag, HIV gp120, HIV Pol, HIV Env, HIV VLP, mutants thereof, and subsequences thereof."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The use of Claim 6 or 7, wherein the vector expresses one or more immunogens selected from the group consisting of HIV Gag, HIV gp120, HIV Pol, HIV Env, HIV VLP, mutants thereof, and subsequences thereof."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["A vector comprising the DNA sequence SEQ ID NO: 1, 2, 3, 4 or 5."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The vector of Claim 9, wherein the vector further comprises a vaccine insert encoding one or more immunogens selected from the group consisting of HIV Gag, HIV gp120, HIV Pol, HIV Env, HIV VLP, measles fusion protein, measles hemagglutinin, measles nucleoprotein, influenza hemagglutinin, mutants thereof, and subsequences thereof; and optionally at least one C3d gene, preferably wherein the one or more immunogens is selected from the group consisting of HIV Gag, HIV gp120, HIV Pol, HIV Env, HIV VLP, mutants thereof, and subsequences thereof."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["A physiologically acceptable composition comprising the vector wherein the vector is a nucleic acid comprising a sequence selected from SEQ ID NO: 1, 2, 3, 4 and 5 for use in a method of immunizing or treating a patient, comprising administering a therapeutically effective amount of the composition and wherein administration of the therapeutically effective amount of the composition is by an intramuscular or intradermal route."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["Use of a physiologically acceptable composition comprising the vector wherein the vector is a nucleic acid comprising a sequence selected from SEQ ID NO: 1, 2, 3, 4 or 5 for the manufacture of a medicament for immunizing a patient comprising administering a therapeutically effective amount of the composition by an intramuscular or intradermal route."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The use of Claim 12, wherein the vector expresses one or more immunogens selected from the group consisting of HIV Gag, HIV gp120, HIV Pol, HIV Env, HIV VLP, measles fusion protein, measles hemagglutinin, measles nucleoprotein, influenza hemagglutinin, mutants thereof, and subsequences thereof; and optionally at least one C3d gene, preferably selected from the group consisting of HIV Gag, HIV gp120, HIV Pol, HIV Env, HIV VLP, mutants thereof, and subsequences thereof."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The use of Claim 12 or 13, further comprising subsequently administering a therapeutically effective amount of a recombinant pox virus vector expressing one or more immunogens selected from the group consisting of HIV Gag, HIV gp120, HIV Pol, HIV Env, HIV VLP, measles fusion protein, measles hemagglutinin, measles nucleoprotein, influenza hemagglutinin, mutants thereof, and subsequences thereof, preferably selected from the group consisting of HIV Gag, HIV gp120, HIV Pol, HIV Env, HIV VLP, mutants thereof, and subsequences thereof."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["A composition comprising the vector of Claim 9 or 10 for use in a method of immunizing or treating a patient in need thereof, comprising a therapeutically effective amount of the composition."],"number":15,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}